KNSAHIGH SIGNALOPERATIONAL10-K

Kiniksa achieved substantially higher revenue growth while advancing its KPL-387 pipeline asset into Phase 2/3 trials for recurrent pericarditis, representing significant commercial and development progress.

The company demonstrates strong commercial execution with meaningful revenue expansion alongside disciplined cost management, as R&D expenses declined while SG&A increased modestly. The advancement of KPL-387 into clinical trials with Mayo Clinic collaboration and planned Phase 2 data in H2 2026 positions the company for potential market expansion beyond its current recurrent pericarditis franchise.

Comparing 2026-02-24 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

The financial profile shows robust growth with revenue substantially higher year-over-year, while the company maintained operational discipline with R&D expenses declining 13.2% and SG&A growing a modest 16.8%. Balance sheet strength improved meaningfully with current assets increasing 58.9% and stockholders' equity growing 29.5%, though accounts receivable declined significantly by 62.6%. The overall picture signals a company successfully scaling its commercial operations while investing in pipeline expansion.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
-62.6%
$41.7M→$15.6M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Revenue
P&L
+60.1%
$423.2M→$677.6M

Strong top-line growth of 60.1% — accelerating demand or successful expansion into new markets.

Current Assets
Balance Sheet
+58.9%
$331.8M→$527.2M

Current assets grew 58.9% — improving short-term liquidity or inventory/receivables build.

Current Liabilities
Balance Sheet
+38.3%
$100.6M→$139.2M

Current liabilities surged 38.3% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+37.9%
$142.1M→$196.0M

Liabilities grew 37.9% — significant increase in debt or obligations, assess impact on financial flexibility.

Total Assets
Balance Sheet
+31.5%
$580.6M→$763.6M

Asset base grew 31.5% — expansion through organic growth, acquisitions, or capital deployment.

Stockholders Equity
Balance Sheet
+29.5%
$438.4M→$567.6M

Equity base grew 29.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

SG&A Expense
P&L
+16.8%
$168.0M→$196.3M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

R&D Expense
P&L
-13.2%
$111.6M→$96.9M

R&D spending cut 13.2% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-25
ADDED
Employer Identification Number) Kiniksa Pharmaceuticals International, plc 105 Piccadilly, Second Floor London , W1J 7NJ England , United Kingdom ( 781 ) 431-9100 (Address, zip code and telephone number, including area code of principal executive offices) Kiniksa Pharmaceuticals Corp.
In December 2024, we initiated a collaborative study agreement with The Mayo Clinic (together with Johns Hopkins University) to investigate the effects of ARCALYST in the treatment of cardiac sarcoidosis.
KPL-387 is an independently developed asset that we believe may expand the recurrent pericarditis market and provide an additional treatment option for patients, with the potential to add the convenience of monthly subcutaneous self-administration with a liquid formulation.
In July 2025, we announced that the Phase 2 dose-focusing portion of the Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis had begun recruiting.
We expect data from the Phase 2 portion of the trial in the second half of 2026 and plan to use the totality of the data to determine further development strategy.
+7 more — sign up free →
REMOVED
Employer Identification Number) Kiniksa Pharmaceuticals International, plc 23 Old Bond Street, Floor 3 London , W1S 4PZ England , United Kingdom ( 781 ) 431-9100 (Address, zip code and telephone number, including area code of principal executive offices) Kiniksa Pharmaceuticals Corp.
100 Hayden Avenue Lexington, MA, 02421 (781) 431-9100 (Address, zip code and telephone number, including area code of agent for service) Kiniksa Pharmaceuticals, Ltd.
Food and Drug Administration (the FDA ) or regulatory authorities in other jurisdictions; potential and ongoing coverage and reimbursement for our products and product candidates, if approved; clinical and commercial activities; research and development costs; timing of regulatory filings and feedback; timing and likelihood of success; and plans and objectives of management for future operations and funding requirements, are forward-looking statements.
Industry and other data Unless otherwise indicated, certain industry data and market data included in this Annual Report were obtained from independent third party surveys, market research, publicly available information, reports of governmental agencies and industry publications and surveys.
KPL-387 is an independently developed asset that we believe has the potential to further advance recurrent pericarditis treatment options for patients by providing the added convenience of monthly subcutaneous dosing with a liquid formulation.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →